<DOC>
	<DOCNO>NCT00687674</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth cancer cell block enzymes need cell growth . Lenalidomide may stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Sorafenib lenalidomide may also stop growth cancer cell block blood flow cancer . Giving sorafenib together lenalidomide dexamethasone may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose sorafenib give together lenalidomide dexamethasone see well work treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Sorafenib , Lenalidomide , Dexamethasone Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose sorafenib tosylate lenalidomide combination dexamethasone patient relapse refractory multiple myeloma . ( phase I ) - To describe toxicity regimen patient . ( phase I ) - To evaluate confirm response patient treat regimen . ( phase II ) Secondary - To correlate clinical effect ( adverse event and/or tumor response activity ) pharmacologic parameter ( pharmacokinetics pharmacodynamics ) and/or biologic result ( correlative laboratory ) . ( phase II ) - To assess overall survival time disease progression patient treat regimen . ( phase II ) OUTLINE : This phase I , dose-escalation study sorafenib tosylate combination lenalidomide follow phase II study . Patients receive oral sorafenib tosylate twice daily day 1-28 , oral lenalidomide daily day 1-21 , oral dexamethasone day 1 , 8 , 15 , 22 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood bone marrow sample collection periodically study laboratory correlative study . Bone marrow plasma sample ( i.e. , fresh marrow aspirate ) assess marrow angiogenesis ( microvessel density ) IHC ; angiogenic capability ( tubular network formation ) vitro angiogenesis assay ; tumor cell proliferation bromo-2-deoxyuridine uptake ; tumor cell apoptosis three-color flow cytometry ( CD38 , CD45 CD138 , 7AAD ) ; expression VEGF soluble VEGF receptor plasma cell enzyme-linked immunosorbent assay . Bone marrow biopsy assess various phosphoprotein IHC ; phosphorylation status ERK1/2 immunoblotting ; pharmacodynamic marker ( e.g. , P70 S6K ) immunoblotting . Blood sample assess surface marker circulate endothelial cell ( CD105 , CD34 , CD146 ) flow cytometry circulate endothelial cell progenitor late colony formation mononuclear cell . The endothelial lineage confirm phenotyping surface marker endothelial cell . After completion study therapy , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 39 patient accrued phase I 44 phase II study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Relapsed refractory disease require treatment Measurable disease , define least 1 follow : Serum monoclonal protein ≥ 1.0 g More 200 mg monoclonal protein urine 24hour electrophoresis Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa lambda free light chain ratio Monoclonal bone marrow plasmacytosis ≥ 30 % ( i.e. , evaluable disease ) No know standard therapy potentially curative patient 's disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,000/μL Platelet count ≥ 75,000/μL Hemoglobin ≥ 9 g/dL Direct bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 3 time ULN ( ≤ 5 time ULN liver involve ) Creatinine ≤ 2.5 time ULN Patients treat untreated POEMS ( PatientOriented Evidence That Matters ) allow , provide satisfy criterion measurable disease No prior malignancy within past year except currently treat basal cell squamous cell skin cancer , carcinoma situ cervix breast , prostate cancer require therapy No active malignancy require treatment would interfere assessment response myeloma protocol treatment INR &lt; 1.5 OR PT/PTT ≤ 1.5 time ULN Patients receive anticoagulation treatment agent warfarin heparin allow Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective contraception 28 day prior , , 28 day discontinuation lenalidomide Willing provide research sample accord test schedule No uncontrolled infection No NYHA classification III IV heart disease No unstable angina ( i.e. , anginal symptom rest ) , newonset angina ( i.e. , begin within past 3 month ) , myocardial infarction within past 6 month No uncontrolled hypertension , define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management No thrombotic embolic event within past 6 month , include cerebrovascular accident transient ischemic attack More 4 week since prior pulmonary hemorrhage bleed event &gt; grade 2 No serious nonhealing wound ulcer More 4 week since prior significant traumatic injury No known positivity HIV infection infectious hepatitis , type A , B , C No known hypersensitivity thalidomide lenalidomide No prior development erythema nodosum characterize desquamate rash take thalidomide similar drug Able take aspirin ( 325 mg ) daily prophylactic anticoagulation PRIOR CONCURRENT THERAPY : Recovered prior chemotherapy , regardless interval since last treatment Prior lenalidomide therapy allow More 4 week since prior experimental therapy More 4 week since prior major surgery open biopsy No concurrent enrollment study involve pharmacologic agent investigative therapy ( i.e. , drug , biologic , immunotherapy approach , gene therapy ) whether symptom control therapeutic intent No concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( i.e. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>